InvestorsHub Logo
Followers 154
Posts 2652
Boards Moderated 0
Alias Born 01/29/2004

Re: boi568 post# 326155

Monday, 08/16/2021 1:17:30 PM

Monday, August 16, 2021 1:17:30 PM

Post# of 463583
Shape ain’t right for toxicity.

This [the molecule’s unique molecular structure] may explain why blarcamasine seems to have no side effects: It is suited to interact with a target that has a unique structure, and the inference would be that blarcamasine cannot interact with other proteins because they are too different in kind from the S1R.

Boi, thanks. Perfectly stated.

That’s it. Blarcamesine simply doesn’t stick or bind to anything else in the cell, other than the sigma-1 receptor protein, where it activates a diversity of propitious “downstream” biochemical outcomes; therefore can’t pathogenically disrupt anything. Toxicologically, it’s inert. Pretty nifty for a drug working in the nervous system.

And, you are right about Anavex 3-71. It will prove even less toxic, and far more potent, acting in microgram, not milligram dosages.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News